European Regulator Recommends GlaxoSmithKline's Dostarlimab Approval

(Alliance News) - GlaxoSmithKline PLC on Friday said the European regulator has adopted a ...

Alliance News 26 February, 2021 | 2:19PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - GlaxoSmithKline PLC on Friday said the European regulator has adopted a positive opinion recommending dostarlimab, one of the final steps in the marketing authorisation procedure.

Dostarlimab is an anti-programmed-death-1 monoclonal antibody, which was recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency for use as monotherapy in women with mismatch repair deficient endometrial cancer, who have progressed on or following prior treatment with a platinum containing regimen.

The Brentford, England-headquartered pharmaceutical company said the application is based on data from the Garnet study.

Meanwhile, dostarlimab is also under review with the US Food & Drug Administration for the treatment of women with recurrent or advanced endometrial cancer. Dostarlimab is not currently approved for use anywhere in the world.

"This positive opinion brings us one step closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe with the hope of improving outcomes. If approved by the European Commission, dostarlimab would be the first anti-PD-1 therapy approved for endometrial cancer in Europe," said Axel Hoos, senior vice president & head of Oncology Research & Development at GSK.

GSK shares were trading 0.4% lower in London on Friday at 1,211.00 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,609.69 GBX -2.06

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures